

Guyana

Country Operational Plan

FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

_	Funding Source			Funding Source	
Agency	GAP	GHP-State	GHP-USAID	Total	Applied Pipeline
DOD				0	300,000
HHS/CDC	575,000	1,913,308		2,488,308	250,000
PC		68,516		68,516	50,071
State		95,000		95,000	0
USAID		2,315,278		2,315,278	1,080,128
Total	575,000	4,392,102	0	4,967,102	1,680,199

Summary of Planned Funding by Budget Code and Agency

			Agency			On Hold	
Budget Code	State	DOD	HHS/CDC	PC	USAID	Amount	Total
НВНС		0	213,333		304,703	0	518,036
НКІД					89,266	0	89,266
HLAB		0	201,351			0	201,351
HTXD					241,501	0	241,501
HTXS			413,017		0	0	413,017
нуст		0	0		254,491	0	254,491
HVMS	58,312	0	732,908	68,516	400,508	0	1,260,244
HVOP		0	61,161	0	178,675	0	239,836
HVSI	36,688	0	453,023	0	225,000	0	714,711
HVTB			0			0	0
мтст			0			0	0
OHSS			259,719		490,118	0	749,837
PDCS			73,719		70,547	0	144,266
PDTX			80,077		60,469	0	140,546
	95,000	0	2,488,308	68,516	2,315,278	0	4,967,102





Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
НВНС	403,415	0
НКІД	89,266	0
НУТВ	0	0
PDCS	62,083	0
Total Technical Area Planned Funding:	554,764	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	165,798	0
HVSI	645,702	0
OHSS	710,288	0
Total Technical Area Planned	4 504 700	0
Funding:	1,521,788	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
HVCT	204,101	0
HVOP	203,519	0
МТСТ	0	0
Total Technical Area Planned Funding:	407,620	0

Technical Area: Treatment

	Budget Code	Budget Code Planned Amount	On Hold Amount
--	-------------	----------------------------	----------------



Total Technical Area Planned Funding:	601,874	0
PDTX	63,916	0
HTXS	387,160	0
HTXD	150,798	0



Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		164
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		165
PMTCT_FO_TA	HIV-infected: Linked to ART		5
	ART HIV-infected: Unknown link		0
	HIV-uninfected: Breastfeeding status unknown		
	HIV-uninfected: Not breastfeeding		
	HIV-uninfected: Still breastfeeding		
	Other: Died		
	Other: In care but no test done		
	Other: Lost to follow-up		
	Other: Transferred out		



	PP_PREV_DSD Percentage		
	of the target population who		
	completed a standardized		
	HIV prevention intervention	n/a	
	including the minimum		
	components during the		
	reporting period (DSD)		
	Number of the target		
	population who completed a		
	standardized HIV prevention		600
	intervention including the		000
	minimum components during		
	the reporting period.		
	Total number of people in the		2,500
PP_PREV_DSD	target population		2,300
	Age/sex: 10-14 Male		0
	Age/sex: 15-19 Male		400
	Age/sex: 20-24 Male		190
	Age/sex: 25-49 Male		0
	Age/sex: 50+ Male		0
	Age/sex: 10-14 Female		0
	Age/sex: 15-19 Female		5
	Age/sex: 20-24 Female		5
	Age/sex: 25-49 Female		0
	Age/sex: 50+ Female		0
	Sum of Age/Sex		600
	disaggregates		600
KP_PREV_DSD	KP_PREV_DSD Percentage		
	of key populations reached		
	with individual and/or small		
	group level HIV preventive	n/a	
	interventions that are based	11/a	
	on evidence and/or meet the		
	minimum standards required		
	(DSD)		



Number of key populations reached with individual and/or small group level HIV preventive interventions that 4,500 are based on evidence and/or meet the minimum standards required Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group 2,500 level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or small group level HIV preventive interventions that are based on evidence and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that ar		h	
and/or small group level HIV 4,500 preventive interventions that 4,500 are based on evidence and/or meet the minimum standards required 1 Total estimated number of key population in the catchment area 1 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group 2,500 level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females ave on evidence and/or meet the minimum standards required) By key population type: Females ave on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key popula	Number of key populations		
preventive interventions that 4,500 are based on evidence and/or meet the minimum standards required Total estimated number of Key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group 2,500 level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key populations Females who inject drugs Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual </td <td>reached with individual</td> <td></td> <td></td>	reached with individual		
are based on evidence and/or meet the minimum standards required Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	and/or small group level HIV		
and/or meet the minimum standards required Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	preventive interventions that		4,500
standards required	are based on evidence		
Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	and/or meet the minimum		
key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females do nevidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	standards required		
catchment areaBy key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small groupindividual and/or small grouplevel HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individualBy key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	Total estimated number of		
By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group 2,500 level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Females who inject drugs (mare based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Females who inject drugs (Females who inject drugs (Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	key population in the		
Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)2,500By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)9By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)9By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual1By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual1	catchment area		
(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)2,500By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	By key population type:		
populations reached with individual and/or small group2,500level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)2,500By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	Female sex workers (FSW)		
individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	(Numerator: Number of key		
level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	populations reached with		
interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	individual and/or small group		2,500
on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	level HIV preventive		
minimum standards required)By key population type:Males who inject drugs (Male PWID) (Numerator:Number of key populationsreached with individualand/or small group level HIVpreventive interventions thatare based on evidenceand/or meet the minimumstandards required)By key population type:Females who inject drugs(Female PWID) (Numerator:Number of key populationsreached with individual	interventions that are based		
By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	on evidence and/or meet the		
Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	minimum standards required)		
Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	By key population type:		
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	Males who inject drugs (
reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	Male PWID) (Numerator:		
and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	Number of key populations		
preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	reached with individual		
are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	and/or small group level HIV		
and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	preventive interventions that		
standards required)By key population type:Females who inject drugs(Female PWID) (Numerator:Number of key populationsreached with individual	are based on evidence		
By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	and/or meet the minimum		
Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	standards required)		
Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual	By key population type:		
(Female PWID) (Numerator: Number of key populations reached with individual			
reached with individual			
	Number of key populations		
and/or small group level HIV			
	and/or small group level HIV		
preventive interventions that			



are based on evidence	
and/or meet the minimum	
standards required)	
By key population type: Men	
who have sex with	
men/Transgender (MSM/TG)	
(Numerator: Number of key	
populations reached with	2 000
individual and/or small group	2,000
level HIV preventive	
interventions that are based	
on evidence and/or meet the	
minimum standards required)	
By key population type:	
MSM/TG who are male sex	
workers (subset MSM/TG)	
(Numerator: Number of key	
populations reached with	
individual and/or small group	
level HIV preventive	
interventions that are based	
on evidence and/or meet the	
minimum standards required)	
By key population type:	
Female sex workers (FSW)	
(Denominator: Total	
estimated number of key	
population in the catchment	
area)	
By key population type:	
Males who inject drugs (
Male PWID) (Denominator:	
Total estimated number of	
key population in the	
catchment area)	
By key population type:	



	Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area) By key population type: Men who have sex with	
	men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	5,494
	By Test Result: Negative	5,240
HTC_TST_DSD	By Test Result: Positive Sum of Test Result disaggregates	254 5,494
	Test Result by Age and Sex: Positive: <1 Male	0
	Test Result by Age and Sex: Positive: 1-4 Male	0
	Test Result by Age and Sex: Positive: 5-9 Male	0



Test Result by Age and Sex: Positive: 10-14 Male	0
Test Result by Age and Sex: Positive: 15-19 Male	6
Test Result by Age and Sex: Positive: 20-24 Male	16
Test Result by Age and Sex: Positive: 25-49 Male	27
Test Result by Age and Sex: Positive: 50+ Male	13
Test Result by Age and Sex: Positive: <1 Female	0
Test Result by Age and Sex: Positive: 1-4 Female	0
Test Result by Age and Sex: Positive: 5-9 Female	0
Test Result by Age and Sex: Positive: 10-14 Female	0
Test Result by Age and Sex: Positive: 15-19 Female	10
Test Result by Age and Sex: Positive: 20-24 Female	13
Test Result by Age and Sex: Positive: 25-49 Female	31
Test Result by Age and Sex: Positive: 50+ Female	6
Test Result by Age and Sex: Negative: <1 Male	5
Test Result by Age and Sex: Negative: 1-4 Male	9
Test Result by Age and Sex: Negative: 5-9 Male	3
Test Result by Age and Sex: Negative: 10-14 Male	14



Test Result by Age and Sex: Negative: 15-19 Male	38
Test Result by Age and Sex:	75
Negative: 20-24 Male	
est Result by Age and Sex:	341
Negative: 25-49 Male	541
Fest Result by Age and Sex:	30
legative: 50+ Male	
est Result by Age and Sex:	10
egative: <1 Female	13
est Result by Age and Sex:	
legative: 1-4 Female	13
est Result by Age and Sex:	
legative: 5-9 Female	11
est Result by Age and Sex:	
Negative: 10-14 Female	20
est Result by Age and Sex:	
legative: 15-19 Female	79
est Result by Age and Sex:	
egative: 20-24 Female	136
est Result by Age and Sex:	
egative: 25-49 Female	463
Test Result by Age and Sex:	
legative: 50+ Female	41
ggregated Age/sex - USE	31
DNLY: <15 Male	51
Aggregated Age/sex - USE	
VITH HQ PERMISSION	2,379
NLY: 15+ Male	2,379
.ggregated Age/sex - USE VITH HQ PERMISSION	57
NLY: <15 Female	57
	0.007
Aggregated Age/sex - USE	3,027



WITH HQ PERMISSION	
ONLY: 15+ Female	
Sum of Aggregated Age/Sex <15	88
Sum of Aggregated Age/Sex 15+	5,406
Sum of Aggregated Age/Sex disaggregates	5,494
Service Delivery Point by Result: Antenatal Clinic - All results	
Service Delivery Point by Result: Antenatal Clinic - Positive	
Service Delivery Point by Result: Antenatal Clinic - Negative	
Service Delivery Point by Result: Labor & delivery - All results	
Service Delivery Point by Result: Labor & delivery - Positive	
Service Delivery Point by Result: Labor & delivery - Negative	
Service Delivery Point by Result: Under 5 Clinic – All results	
Service Delivery Point by Result: Under 5 Clinic - Positive	
Service Delivery Point by Result: Under 5 Clinic - Negative	



ц — Ц	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic – All Results	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Positive	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Negative	
Service Delivery Point by	
Result: Tuberculosis – All	
results	
Service Delivery Point by	
Result: Tuberculosis -	
Positive	
Service Delivery Point by	
Result: Tuberculosis -	
Negative	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections – All Results	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Positive	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Negative	
Service Delivery Point by	
Result: Outpatient	
Department – All Results	
Service Delivery Point by	
Result: Outpatient	
Department - Positive	
Service Delivery Point by	
Result: Outpatient	



Department - Negative	
Service Delivery Point by	
Result: Inpatient – All	
Results	
Service Delivery Point by	
Result: Inpatient - Positive	
Service Delivery Point by	
Result: Inpatient - Negative	
Service Delivery Point by	
Result: HIV care and	
treatment clinic – All Results	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Positive	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Negative	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision – All	
Results	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Positive	
Service Delivery Point by	
Result: Voluntary Medical	
Male Circumcision - Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) – All	
Results	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Positive	



Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (co-located) -	
Negative	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) – All	
Results	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) –	
Positive	
Service Delivery Point by	
Result: Voluntary Counseling	
& Testing (stand alone) –	
Negative	
Service Delivery Point by	
Result: Mobile – All Results	
Service Delivery Point by	
Result: Mobile - Positive	
Service Delivery Point by	
Result: Mobile - Negative	
Service Delivery Point by	
Result: Home-based – All	
Results	
Service Delivery Point by	
Result: Home-based -	
Positive	
Service Delivery Point by	
Result: Home-based -	
Negative	
Service Delivery Point by	
Result: Other – All Results	
Service Delivery Point by	
Result: Other - Positive	



	Service Delivery Point by	
	Result: Other - Negative	
	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	800
	By Test Result: Negative	
	By Test Result: Positive	
	Sum of Test Result disaggregates	
	Test Result by Age and Sex: Positive: <1 Male	
	Test Result by Age and Sex: Positive: 1-4 Male	
	Test Result by Age and Sex: Positive: 5-9 Male	
HTC_TST_TA	Test Result by Age and Sex: Positive: 10-14 Male	
	Test Result by Age and Sex: Positive: 15-19 Male	
	Test Result by Age and Sex: Positive: 20-24 Male	
	Test Result by Age and Sex: Positive: 25-49 Male	
	Test Result by Age and Sex: Positive: 50+ Male	
	Test Result by Age and Sex: Positive: <1 Female	
	Test Result by Age and Sex: Positive: 1-4 Female	
	Test Result by Age and Sex: Positive: 5-9 Female	
	Test Result by Age and Sex:	



Positive: 10-14 Female	
Test Result by Age and Sex:	
Positive: 15-19 Female	
Test Result by Age and Sex:	
Positive: 20-24 Female	
Test Result by Age and Sex:	
Positive: 25-49 Female	
Test Result by Age and Sex:	
Positive: 50+ Female	
Test Result by Age and Sex:	
Negative: <1 Male	
Test Result by Age and Sex:	
Negative: 1-4 Male	
Test Result by Age and Sex:	
Negative: 5-9 Male	
Test Result by Age and Sex:	
Negative: 10-14 Male	
Test Result by Age and Sex: Negative: 15-19 Male	
Test Result by Age and Sex:	
Negative: 20-24 Male	
Test Result by Age and Sex:	
Negative: 25-49 Male	
Test Result by Age and Sex:	
Negative: 50+ Male	
Test Result by Age and Sex:	
Negative: <1 Female	
Test Result by Age and Sex:	
Negative: 1-4 Female	
Test Result by Age and Sex:	
Negative: 5-9 Female	
Test Result by Age and Sex:	
Negative: 10-14 Female	
Test Result by Age and Sex:	



	Negative: 15-19 Female
	Test Result by Age and Sex:
	Negative: 20-24 Female
	Test Result by Age and Sex:
	Negative: 25-49 Female
	Test Result by Age and Sex:
	Negative: 50+ Female
	Aggregated Age/sex - USE
0	WITH HQ PERMISSION
	ONLY: <15 Male
	Aggregated Age/sex - USE
800	WITH HQ PERMISSION
	ONLY: 15+ Male
	Aggregated Age/sex - USE
0	WITH HQ PERMISSION
	ONLY: <15 Female
	Aggregated Age/sex - USE
0	/ITH HQ PERMISSION
	NLY: 15+ Female
0	um of Aggregated Age/Sex
	15
800	um of Aggregated Age/Sex
	5+
800	Sum of Aggregated Age/Sex
800	isaggregates
	Service Delivery Point by
	Result: Antenatal Clinic - All
	results
	Service Delivery Point by
	Result: Antenatal Clinic -
	ositive
	ervice Delivery Point by
	esult: Antenatal Clinic -
	legative



Service Delivery Point by	
Result: Labor & delivery - All	
results	
Service Delivery Point by	
Result: Labor & delivery -	
Positive	
Service Delivery Point by	
Result: Labor & delivery -	
Negative	
Service Delivery Point by	
Result: Under 5 Clinic – All	
results	
Service Delivery Point by	
Result: Under 5 Clinic -	
Positive	
Service Delivery Point by	
Result: Under 5 Clinic -	
Negative	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic – All Results	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Positive	
Service Delivery Point by	
Result: Maternal and Child	
Health Clinic - Negative	
Service Delivery Point by	
Result: Tuberculosis – All	
results	
Service Delivery Point by	
Result: Tuberculosis -	
Positive	
Service Delivery Point by	
Result: Tuberculosis -	



Negative	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections – All Results	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Positive	
Service Delivery Point by	
Result: Sexually Transmitted	
Infections - Negative	
Service Delivery Point by	
Result: Outpatient	
Department – All Results	
Service Delivery Point by	
Result: Outpatient	
Department - Positive	
Service Delivery Point by	
Result: Outpatient	
Department - Negative	
Service Delivery Point by	
Result: Inpatient – All	
Results	
Service Delivery Point by	
Result: Inpatient - Positive	
Service Delivery Point by	
Result: Inpatient - Negative	
Service Delivery Point by	
Result: HIV care and	
treatment clinic – All Results	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Positive	
Service Delivery Point by	
Result: HIV care and	
treatment clinic - Negative	



r	
Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results Service Delivery Point by	
Result: Voluntary Medical Male Circumcision - Positive Service Delivery Point by Result: Voluntary Medical	
Male Circumcision - Negative Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results	
Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive	
Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative	
Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All	
Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive	
Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative	
Service Delivery Point by Result: Mobile – All Results	



Service Delivery Point by	
Result: Mobile - Positive	
Service Delivery Point by	
Result: Mobile - Negative	
Service Delivery Point by	
Result: Home-based – All	
Results	
Service Delivery Point by	
Result: Home-based -	
Positive	
Service Delivery Point by	
Result: Home-based -	
Negative	
Service Delivery Point by	
Result: Other – All Results	
Service Delivery Point by	
Result: Other - Positive	
Service Delivery Point by	
Result: Other - Negative	
Test Result by Aggregated	
Age and Sex: Negative <15	
Male	
Test Result by Aggregated	
Age and Sex: Negative 15+	
Male	
Test Result by Aggregated	
Age and Sex: Negative <15	
Female	
Test Result by Aggregated	
Age and Sex: Negative 15+	
Female	
Test Result by Aggregated	
Age and Sex: Positive <15	
Male	
Test Result by Aggregated	



	Age and Sex: Positive 15+ Male	
	Test Result by Aggregated Age and Sex: Positive <15 Female	
	Test Result by Aggregated Age and Sex: Positive 15+ Female	
	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	539
	Age/Sex: <10 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25+ Male	
	Age/Sex: <10 Female	
GEND_NORM_DSD	Age/Sex: 10-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25+ Female	
	By Age: 0-9	
	By Age: 10-14	
	By Age: 15-19	
	By Age: 20-24	
	By Age: 25+	
	Sum of Age disaggregates	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC	840
	programs to access HIV services	



[
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	Age/Sex: 18-24 Male	
	Age/Sex: 25+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	Age/Sex: 18+ Female	
	Age/Sex: 18-24 Female	
	Age/Sex: 25+ Female	
	Sum of Age/Sex	
	disaggregates	
	Number of active	
	beneficiaries served by	
	PEPFAR OVC programs for	2,000
	children and families affected by HIV/AIDS	
	Age/Sex: <1 Male	4
	Age/Sex: 1-4 Male	52
	Age/Sex: 5-9 Male	120
OVC_SERV_DSD	Age/Sex: 10-14 Male	120
	Age/Sex: 15-17 Male	194
	By: Age/sex: Male 18-24 By: Age/sex: Male 25+	225
	Age/Sex: <1 Female	228
	Age/Sex: <1 Female	8
		41
	Age/Sex: 5-9 Female	156



Age/Sex: 10-14 Female	159
Age/Sex: 15-17 Female	106
By: Age/sex: 18-24 Female	323
By: Age/sex: 25+ Female	324
Sum of Age/Sex	
disaggregates	900
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female <1	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Education Support	
Female 25+	
Required only for DREAMS	



countries - By service, age and sex: Education Support		
Male <1		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Education Support		
Male 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female <1	1	
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Female 1-4		



Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 10-14	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 15-17	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 18-24	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Female 25+	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male <1	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 1-4	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	
Programs Male 5-9	
Required only for DREAMS	
countries - By service, age	
and sex: Parenting/Caregiver	



Programs Male 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Male 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Male 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Parenting/Caregiver		
Programs Male 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Social Protection		
Female 15-17		
Required only for DREAMS		
countries - By service, age		
	I	



۱ ۱	
and sex: Social Protection Female 18-24	
Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	
Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	
Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	
Required only for DREAMS	



	1	
countries - By service, age		
and sex: Economic		
Strengthening Female <1		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 1-4		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 5-9		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 10-14		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 15-17		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 18-24		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Female 25+		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
Strengthening Male <1		
Required only for DREAMS		
countries - By service, age		
and sex: Economic		
 Strengthening Male 1-4		



	Required only for DREAMS	
	countries - By service, age	
	and sex: Economic	
	Strengthening Male 5-9	
	Required only for DREAMS	
	countries - By service, age	
	and sex: Economic	
	Strengthening Male 10-14	
	Required only for DREAMS	
	countries - By service, age	
	and sex: Economic	
	Strengthening Male 15-17	
	Required only for DREAMS	
	countries - By service, age	
	and sex: Economic	
	Strengthening Male 18-24	
	Required only for DREAMS	
	countries - By service, age	
	and sex: Economic	
	Strengthening Male 25+	
	Number of HIV positive	
	adults and children who	
	received at least one of the	
	following during the reporting	1,722
	period: clinical assessment	
	(WHO staging) OR CD4	
	count OR viral load	
CARE_CURR_DSD	Age/sex: <1 Male	0
	Age/sex: 1-4 Male	5
	Age/sex: 5-9 Male	13
	Age/sex: 10-14 Male	28
	Age/sex: 15-19 Male	13
	Age/sex: 20-24 Male	42
	Age/sex: 25-49 Male	433
	Age/sex: 50+ Male	183
L		



	Age/sex: <1 Female	0
	Age/sex: 1-4 Female	1
	Age/sex: 5-9 Female	4
	Age/sex: 10-14 Female	24
	Age/sex: 15-19 Female	23
	Age/sex: 20-24 Female	38
	Age/sex: 25-49 Female	721
	Age/sex: 50+ Female	194
	Sun of Age/Sex disaggregates	1,722
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	47
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	672
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	29
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	974
	Sum of Aggregated Age/Sex disaggregates	1,722
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,191
	Age/sex: <1 Male	
	Age/sex: 1-4 Male	
	Age/sex: 5-9 Male	



	Age/sex: 10-14 Male	
	Age/sex: 15-19 Male	
	Age/sex: 20-24 Male	
	Age/sex: 25-49 Male	
	Age/sex: 50+ Male	
	Age/sex: <1 Female	
	Age/sex: 1-4 Female	
	Age/sex: 5-9 Female	
	Age/sex: 10-14 Female	
	Age/sex: 15-19 Female	
	Age/sex: 20-24 Female	
	Age/sex: 25-49 Female	
	Age/sex: 50+ Female	
	Sum of Age/Sex	
	disaggregates	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	43
	ONLY: <15 Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	1,054
	ONLY: 15+ Male	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	38
	ONLY: <15 Female	
	Aggregated Age/sex - USE	
	WITH HQ PERMISSION	1,056
	ONLY: 15+ Female	
	Sum of Aggregated Age/Sex	2,191
	disaggregates	
	Number of HIV-infected	
	adults and children newly	
CARE_NEW_DSD	enrolled in clinical care	165
	during the reporting period	
	and received at least one of	



	the following at enrollment:	
	clinical assessment (WHO	
	staging) OR CD4 count OR	
	viral load	
	Age/sex: <1 Male	0
	Age/sex: 1-4 Male	0
	Age/sex: 5-9 Male	0
	Age/sex: 10-14 Male	1
	Age/sex: 15-19 Male	3
	Age/sex: 20-24 Male	9
	Age/sex: 25-49 Male	44
	Age/sex: 50+ Male	16
	Age/sex: <1 Female	0
	Age/sex: 1-4 Female	0
	Age/sex: 5-9 Female	0
	Age/sex: 10-14 Female	2
	Age/sex: 15-19 Female	6
	Age/sex: 20-24 Female	11
	Age/sex: 25-49 Female	56
	Age/sex: 50+ Female	17
	Sum of Age/sex disaggregates	165
	Aggregated Age/sex: <15 Male	1
	Aggregated Age/sex: 15+ Male	71
	Aggregated Age/sex: <15 Female	2
	Aggregated Age/sex: 15+ Female	91
	Sum of Aggregated Age/sex disaggregates	165
RE_NEW_TA	Number of HIV-infected	228



adults and children newly enrolled in clinical care	
enrolled in clinical care	
during the reporting period	
and received at least one of	
the following at enrollment:	
clinical assessment (WHO	
staging) OR CD4 count OR	
viral load	
Age/sex: <1 Female	
Age/sex: 1-4 Female	
Age/sex: 5-9 Female	
Age/sex: 10-14 Female	
Age/sex: 15-19 Female	
Age/sex: 20-24 Female	
Age/sex: 25-49 Female	
Age/sex: 50+ Female	
Age/sex: <1 Male	
Age/sex: 1-4 Male	
Age/sex: 5-9 Male	
Age/sex: 10-14 Male	
Age/sex: 15-19 Male	
Age/sex: 20-24 Male	
Age/sex: 25-49 Male	
Age/sex: 50+ Male	
Aggregated Age/sex: <15	7
Female	1
Aggregated Age/sex: <15	-
Male	1
Aggregated Age/sex: 15+	00
Female	90
Aggregated Age/sex: 15+	104
Male	124
Sum of Aggregated Age/sex	165



	disaggregates		
	Sum of age/sex		
	disaggregates		
	TB_IPT_DSD Proportion of		
	PLHIV newly enrolled in HIV		
	clinical care who start	n/a	
	isoniazid preventive therapy		
	(IPT)		
	The number of PLHIV newly		
	enrolled in HIV care who		6
	start IPT during the reporting		U
	period		
	Number of HIV-positive		
	adults and children newly		
	enrolled in clinical care		
	during the reporting period and received at least one of		
	the following at enrollment:		
	clinical assessment (WHO		
TB_IPT_DSD	staging) OR CD4 count OR		
	viral load		
	Age: <1		0
	Age: 1-4		0
	Age: 5-9		0
	Age: 10-14		0
	Age: 15-19		1
	Age: 20+		5
	Sum of Age disaggregates		6
	Age (Aggregated)- USE		
	WITH HQ PERMISSION		0
	ONLY: <15		
	Age (Aggregated)- USE		
	WITH HQ PERMISSION		6
	ONLY: 15+		
	Sex: Male		4



	Sex: Female		2
	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period		74
TB_IPT_TA	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		
	Age (Aggregated)- USE WITH HQ PERMISSION		
	ONLY: 15+		
	Sex: Male Sex: Female		41 33



	TB_SCREEN_DSD		
	Percentage of PLHIV who		
	were screened for TB	n/a	
	symptoms at the last clinical		
	visit to an HIV care facility		
	during the reporting period.		
	The number of PLHIV who		
	were screened for TB		
	symptoms at the last clinical		1,722
	visit to an HIV care facility		
	during the reporting period		
	Number of HIV positive		
	adults and children who		
	received at least one of the		
	following during the reporting		1,722
	period: clinical assessment		
	(WHO staging) OR CD4		
	count OR viral load		
TB_SCREEN_DSD	Age: <1		0
	Age: 1-4		6
	Age: 5-9		18
	Age: 10-14		52
	Age: 15-19		36
	Age: 20+		1,610
	Sum of Age disaggregates		1,722
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		76
	<15		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		1,646
	15+		
	Sum of Aggregated Age	T	
	disaggregates		1,722
	Sex: Male		719
	Sex: Female		1,003



	Sum of Sex disaggregates		1,722
	TB_SCREEN_TA		
	Percentage of PLHIV who		
	were screened for TB	2/2	
	symptoms at the last clinical	n/a	
	visit to an HIV care facility		
	during the reporting period.		
	The number of PLHIV who		
	were screened for TB		
	symptoms at the last clinical		2,191
	visit to an HIV care facility		
	during the reporting period		
	Number of HIV positive		
	adults and children who		
	received at least one of the		
	following during the reporting		2,191
	period: clinical assessment		
	(WHO staging) OR CD4		
TB_SCREEN_TA	count OR viral load		
	Age: <1		
	Age: 1-4		
	Age: 5-9		
	Age: 10-14		
	Age: 15-19		
	Age: 20+		
	Sum of Age disaggregates		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		81
	<15		
	Aggregated Age - USE WITH		
	HQ PERMISSION ONLY:		2,110
	15+		
	Sum of Aggregated Age		
	disaggregates		2,191
	Sex: Female		1,095



	Sex: Male		1,096
	Sum of Sex disaggregates		2,191
	PMTCT_EID_TA Percent of infants born to HIV-positive		
	women that receive a	n/a	
	virological HIV test within 12		
	months of birth (TA)		
	Number of infants who had a virologic HIV test within 12 months of birth during the		144
	reporting period Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
PMTCT_EID_TA	By infants who received a virologic test within 2 months of birth		107
	By infants who received their first virologic HIV test between 2 and 12 months of age		37
	Sum of Infant Age disaggregates		144
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		0
	Number of infants with a positive virological test result within 12 months of birth		2
CARE_COMM_DSD	Number of HIV-infected		1,307



	adults and children receiving	
	care and support services	
	outside of the health facilitY	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
	Number of adults and	
	children receiving	1,510
	antiretroviral therapy (ART)	
TX_CURR_DSD	Age/Sex: <1 Male	0
	Age/Sex: 1-4 Male	5
	Age/Sex: 5-14 Male	28
	Age/Sex: 15-19 Male	17
	Age/Sex: 20+ Male	561
	Age/Sex: <1 Female	0
	Age/Sex: 1-4 Female	2
	Age/Sex: 5-14 Female	23
	Age/Sex: 15-19 Female	34
	Age/Sex: 20+ Female	840
	J	0.0



	Aggregated Age/Sex: <1 Male	0
	Aggregated Age/Sex: <1 Female	0
	Aggregated Age/Sex: 15+ Male	578
	Aggregated Age/Sex: 1-14 Female	25
	Aggregated Age/Sex: 15+ Female	874
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,452
	Sum of Aggregated Age/Sex disaggregates	1,452
	Aggregated Age/Sex: 1-14 Male	33
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	58
	Number of adults and children receiving antiretroviral therapy (ART)	1,845
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
TX_CURR_TA	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	



	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	0
	Aggregated Age/Sex: <1 Female	0
	Aggregated Age/Sex: 1-14 Male	37
	Aggregated Age/Sex: 15+ Male	934
	Aggregated Age/Sex: 1-14 Female	41
	Aggregated Age/Sex: 15+ Female	833
	Sum of Aggregated Age/Sex <15	
	Sum of Aggregated Age/Sex 15+	1,767
	Sum of Aggregated Age/Sex disaggregates	1,767
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	78
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	178
	By Age/Sex: <1 Male	0
	By Age/Sex: 1-4 Male	0
	By Age/Sex: 5-9 Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	2
	By Age/Sex: 15-19 Male	7
	By Age/Sex: 20-24 Male	11
	By Age/Sex: 25-49 Male	41
	By Age/Sex: 50+ Male	16
	By Age/Sex: <1 Female	0



	By Age/Sex: 1-4 Female	0
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	0
		3
	By Age/Sex: 15-19 Female	8
	By Age/Sex: 20-24 Female	15
	By Age/Sex: 25-49 Female	60
	By Age/Sex: 50+ Female	15
	Sum of Age/Sex disaggregates	178
	Aggregated Grouping by Age: <1 Male	0
	Aggregated Grouping by Age/Sex: 1-14 Male	2
	Aggregated Grouping by Age/Sex: 15+ Male	74
	Aggregated Grouping by Age/Sex: <1 Female	0
	Aggregated Grouping by Age/Sex: 15+ Female	99
	Sum of Aggregated Age/Sex disaggregates	173
	Pregnancy status	11
	Breastfeeding status	0
	Aggregated Grouping by Age/Sex: 1-14 Female	3
	Number of adults and children newly enrolled on antiretroviral therapy (ART)	227
	By Age/Sex: <1 Male	
TX_NEW_TA	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	



		r	r
	By Age/Sex: 20-24 Male		
	By Age/Sex: 25-49 Male		
	By Age/Sex: 50+ Male		
	By Age/Sex: <1 Female		
	By Age/Sex: 1-4 Female		
	By Age/Sex: 5-9 Female		
	By Age/Sex: 10-14 Female		
	By Age/Sex: 15-19 Female		
	By Age/Sex: 20-24 Female		
	By Age/Sex: 25-49 Female		
	By Age/Sex: 50+ Female		
	Sum of Age/Sex		
	disaggregates		
	Aggregated Grouping by		0
	Age: <1 Male		0
	Aggregated Grouping by		7
	Age/Sex: 1-14 Male		/
	Aggregated Grouping by		118
	Age/Sex: 15+ Male		110
	Aggregated Grouping by		0
	Age: <1 Female		
	Aggregated Grouping by		5
	Age/Sex: 1-14 Female		
	Aggregated Grouping by		97
	Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex		215
	disaggregates		
	Pregnancy status		9
	Breastfeeding status		0
	TX_RET_DSD Percent of adults and children known to		
TX_RET_DSD	be alive and on treatment 12	n/a	
	months after initiation of		
		1	



ι.	
antiretroviral therapy	
Number of adults and	
children who are still alive	110
and on treatment at 12	119
months after initiating ART	
Total number of adults and	
children who initiated ART in	
the 12 months prior to the	
beginning of the reporting	
period, including those who	140
have died, those who have	
stopped ART, and those lost	
to follow-up	
Age/Sex: <5 Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	0
12 months after initiating	
ART)	
Age/Sex: 5-14 Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	0
12 months after initiating	
ART)	
Age/Sex: 15-19 Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	14
12 months after initiating	
ART)	
Age/Sex: 20+ Male	
(Numerator: Number of	
adults and children who are	41
still alive and on treatment at	
12 months after initiating	



ART)	
Age/Sex: <5 Female	
Numerator: Number of	
adults and children who are	
still alive and on treatment at	0
12 months after initiating	
ART)	
Age/Sex: 5-14 Female	
(Numerator: Number of	
adults and children who are	0
still alive and on treatment at	0
12 months after initiating	
ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	13
12 months after initiating	
ART)	
Age/Sex: 20+ Female	
Numerator: Number of	
adults and children who are	
still alive and on treatment at	51
12 months after initiating	
ART)	
Age/Sex: <5 Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	0
of the reporting period,	0
ncluding those who have	
ied, those who have	
topped ART, and those lost	
o follow-up)	
Age/Sex: 5-14 Male	0
·	



(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	10
of the reporting period,	18
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	10
of the reporting period,	49
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: <5 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	0
months prior to the beginning	
of the reporting period,	
including those who have	



<u></u>	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 5-14 Female	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	0
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 15-19 Female	
(Denominator: Total number	
of adults and children who	
nitiated ART in the 12	
months prior to the beginning	
of the reporting period,	17
ncluding those who have	
lied, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Female	
(Denominator: Total number	
of adults and children who	
nitiated ART in the 12	
months prior to the beginning	
of the reporting period,	56
including those who have	
died, those who have	
stopped ART, and those lost	
o follow-up)	
lumerator by Status:	15
Pregnant	
Numerator by Status:	



	Breastfeeding		
	Denominator by Status:		
	Pregnant		15
	Denominator by Status:		
	Breastfeeding		
	TX_RET_TA Percent of		
	adults and children known to		
	be alive and on treatment 12	n/a	
	months after initiation of		
	antiretroviral therapy		
	Number of adults and		-
	children who are still alive		455
	and on treatment at 12		155
	months after initiating ART		
	Total number of adults and		
	children who initiated ART in		
	the 12 months prior to the		
	beginning of the reporting		(=0
	period, including those who		176
	have died, those who have		
TX_RET_TA	stopped ART, and those lost		
	to follow-up		
	Age/Sex: <5 Male		
	(Numerator: Number of		
	adults and children who are		
	still alive and on treatment at		
	12 months after initiating		
	ART)		
	Age/Sex: 5-14 Male		
	(Numerator: Number of		
	adults and children who are		
	still alive and on treatment at		
	12 months after initiating		
	ART)		
	Age/Sex: 15-19 Male		



(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 20+ Male	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: <5 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 5-14 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 15-19 Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: 20+ Female	
(Numerator: Number of	
adults and children who are	
still alive and on treatment at	
12 months after initiating	
ART)	
Age/Sex: <5 Male	



(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 5-14 Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 15-19 Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	
died, those who have	
stopped ART, and those lost	
to follow-up)	
Age/Sex: 20+ Male	
(Denominator: Total number	
of adults and children who	
initiated ART in the 12	
months prior to the beginning	
of the reporting period,	
including those who have	



	İ	
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: <5 Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 5-14 Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
-		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 15-19 Female		
(Denominator: Total number		
of adults and children who		
initiated ART in the 12		
months prior to the beginning		
of the reporting period,		
including those who have		
died, those who have		
stopped ART, and those lost		
to follow-up)		
Age/Sex: 20+ Female		
(Denominator: Total number		
of adults and children who		



	initiated ART in the 12		
	months prior to the beginning		
	of the reporting period,		
	including those who have		
	died, those who have		
	stopped ART, and those lost		
	to follow-up)		
	Numerator by Status:		
	Pregnant		
	Numerator by Status:		
	Breastfeeding		
	Denominator by Status:		
	Pregnant		
	Denominator by Status:		
	Breastfeeding		
	TX_VIRAL_DSD Percentage		
	of ART patients with an	n/a	
	undetectable viral load at 12	n/a	
	months after initiation of ART		
	Number of adult and		
	pediatric ART patients with a		
	viral load result documented		1,011
	in the patient medical record		
	within the past 12 months		
	Number of adults and		
TX_VIRAL_DSD	children on ART at least 6		1,264
	months whose medical		1,204
	records were reviewed		
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		3
	Age/Sex: 5-14 Male		28
	Age/Sex: 15-19 Male		23
	Age/Sex: 20+ Male		430
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		1



	Age/Sex: 5-14 Female		30
	Age/Sex: 15-19 Female		21
	Age/Sex: 20+ Female		475
	Results Category: Undetectable		940
	Results Category: Detectable		71
	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		1,630
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		1,824
TX_VIRAL_TA	Age/Sex: <1 Male		
	Age/Sex: 1-4 Male		
	Age/Sex: 5-14 Male		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+Male		
	Age/Sex: <1 Female		
	Age/Ses: 1-4 Female		
	Age/Sex: 5-14 Female		
	Age/Sex: 15-19 Female		
	Age/Sex: 20+ Female		
	Result Category: Undetectable		
	Result Category: Detectable		
LAB_ACC_DSD	Number of PEPFAR-supported testing		1



	facilities (laboratories) that	
	are recognized by national,	
	regional, or international	
	standards for accreditation or	
	have achieved a minimal	
	acceptable level towards	
	attainment of such	
	accreditation	
	Number of	
	PEPFAR-supported testing	
	facilities (laboratories) that	
	are recognized by national,	
	regional, or international	
LAB_ACC_TA	standards for accreditation or	1
	have achieved a minimal	
	acceptable level towards	
	attainment of such	
	accreditation	
	Number of	
	PEPFAR-supported testing	
	facilities with capacity to	4
LAB_CAP_DSD	perform clinical laboratory	
	tests	
	By clinical laboratories	3
	By Point-of-care testing sites	1
	Number of	
	PEPFAR-supported testing	
	facilities with capacity to	5
LAB_CAP_TA	perform clinical laboratory	
	tests	
	By clinical laboratories	1
	By Point-of-care testing sites	4
	Percentage of laboratories	
LAB_PT_DSD	and POC testing sites that	
	perform HIV diagnostic	



r	
testing that participate and	
successfully pass in an	
analyte-specific proficiency	
testing (PT) program	
HIV serologic/diagnostic	
testing: Number of	4
laboratories that perform this	4
testing	
HIV serologic/diagnostic	
testing: Number of	4
laboratories that participate	4
in this PT program	
HIV serologic/diagnostic	
testing: Number of	
laboratories that achieve	4
acceptable successful	4
passing criteria in this PT	
program	
CD4: Number of laboratories	
that perform this testing	
CD4: Number of laboratories	
that participate in this PT	
program	
CD4: Number of laboratories	
that achieve acceptable	
successful passing criteria in	
this PT program	
Early infant diagnostics:	
Number of laboratories that	
perform this testing	
Early infant diagnostics:	
Number of laboratories that	
participate in this PT	
program	
Early infant diagnostics:	
 ,	



Number of laboratories that achieve acceptable successful passing criteria in this PT program	
HIV viral load: Number of laboratories that perform this testing	
HIV viral load: Number of laboratories that participate in this PT program	
HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	
TB diagnostics (AFB microscopy): Number of laboratories that perform this testing	2
TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program	2
TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program	2
TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing	
 TB diagnostics (Xpert MTB/RIF): Number of	



	laboratories that participate	
	in this PT program	
	TB diagnostics (Xpert	
	MTB/RIF): Number of	
	laboratories that achieve	
	acceptable successful	
	passing criteria in this PT	
	program	
	TB diagnostics	
	(Culture/DST): Number of	
	laboratories that perform this	
	testing	
	TB diagnostics (Culture/DST): Number of	
	laboratories that participate	
	in this PT program	
	TB diagnostics (Culture/DST): Number of	
	laboratories that achieve	
	acceptable successful	
	passing criteria in this PT	
	program	
	Percentage of laboratories	
	and POC testing sites that	
	perform HIV diagnostic	
	testing that participate and	
	successfully pass in an	
	analyte-specific proficiency	
	testing (PT) program	
LAB_PT_TA	CD4: Number of laboratories	
	that achieve acceptable	
	successful passing criteria in	1
	this PT program	
	CD4: Number of laboratories	
	that participate in this PT	1
	program	
L	1 J	



CD4: Number of laboratories	1
that perform this testing	
Early infant diagnostics:	
Number of laboratories that	
achieve acceptable	1
successful passing criteria in	
this PT program	
Early infant diagnostics:	
Number of laboratories that	
participate in this PT	1
program	
Early infant diagnostics:	
Number of laboratories that	1
perform this testing	
HIV serologic/diagnostic	
testing: Number of	
laboratories that achieve	_
acceptable successful	5
passing criteria in this PT	
program	
HIV serologic/diagnostic	
testing: Number of	-
laboratories that participate	5
in this PT program	
HIV serologic/diagnostic	
testing: Number of	-
laboratories that perform this	5
testing	
HIV viral load: Number of	
laboratories that achieve	
acceptable successful	1
passing criteria in this PT	
program	
HIV viral load: Number of	
laboratories that participate	1



in this PT program	
in this PT program	
HIV viral load: Number of	
laboratories that perform this	1
testing	
TB diagnostics (AFB	
microscopy): Number of	
laboratories that achieve	1
acceptable successful	•
passing criteria in this PT	
program	
TB diagnostics (AFB	
microscopy): Number of	1
laboratories that participate	1
in this PT program	
TB diagnostics (AFB	
microscopy): Number of	
laboratories that perform this	1
testing	
TB diagnostics (Xpert	
MTB/RIF): Number of	
laboratories that achieve	
acceptable successful	1
passing criteria in this PT	
program	
TB diagnostics (Xpert	
MTB/RIF): Number of	1
laboratories that participate	
in this PT program	
TB diagnostics (Xpert	
MTB/RIF): Number of	1
laboratories that perform this	•
testing	
TB diagnostics	
(Culture/DST): Number of	1
laboratories that achieve	



	acceptable successful passing criteria in this PT		
	program		
	TB diagnostics		
	(Culture/DST): Number of		
	laboratories that participate		1
	in this PT program		
	TB diagnostics		
	(Culture/DST): Number of		1
	laboratories that perform this		1
	testing		
	TX_UNDETECT_DSD		
	Proportion of viral load tests		
	with an undetectable viral	n/a	
	load (<1000 copies/ml)		
	Number of viral load tests		
	from adult and pediatric ART		
	patients conducted in the		803
	past 12 months with a viral		
	load <1,000 copies/ml		
	Number of viral load tests		
TX_UNDETECT_DSD	performed from adults and		944
TX_UNDETECT_DOD	children on ART within the		011
	current reporting period		
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		3
	Age/Sex: 5-14 Male		27
	Age/Sex: 15-19 Male		9
	Age/Sex: 20+ Male		339
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		1
	Age/Sex: 5-14 Female		26
	Age/Sex: 15-19 Female		15



	Age/Sex: 20+ Female		383
	Pregnant		50
	Breastfeeding		0
	Test indication: Routine monitoring		803
	Test indication: Targeted monitoring		
	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		1,540
TX_UNDETECT_TA	Number of viral load tests performed from adults and children on ART within the current reporting period		1,824
	Age/Sex: <1 Female Age/Sex: <1 Male		
	Age/Sex: 1-4 Female		
	Age/Sex: 1-4 Male		
	Age/Sex: 15-19 Female		
	Age/Sex: 15-19 Male		
	Age/Sex: 20+ Female		
	Age/Sex: 20+ Male		
	Age/Sex: 5-14 Female		
	Age/Sex: 5-14 Male		
	Breastfeeding		
	Pregnant		
	Test indication: Routine		



	monitoring		
Test indication: Targeted			
	monitoring		
	FPINT_SITE_DSD Family		
	Planning and HIV		
	Integration: Percentage of		
	HIV service delivery points	n/a	
	supported by PEPFAR that	n/a	
	are directly providing		
	integrated voluntary family		
	planning services		
	Number of service delivery		
	points supported by PEPFAR		
	for HIV services that are		1
	directly providing integrated		1
	voluntary family planning		
FPINT_SITE_DSD	services		
	Total number of		
	PEPFAR-supported HIV		2
	service delivery points:		2
	PMTCT, Care and Treatment		
	Service delivery type: Care		
	and Support		
	Service delivery type:		
	Treatment		1
	Service delivery type:		
	PMTCT		
	Sum of Service delivery type		
	(Care, Tx and PMTCT)		
	disaggregates		
	FPINT_SITE_TA Family		
	Planning and HIV		
FPINT_SITE_TA	Integration: Percentage of	n/a	
	HIV service delivery points		
	supported by PEPFAR that		



1	
are directly providing	
integrated voluntary family	
planning services	
Number of service delivery	
points supported by PEPFAR	
for HIV services that are	
directly providing integrated	8
voluntary family planning	
services	
Total number of	
PEPFAR-supported HIV	
service delivery points:	8
PMTCT, Care and Treatment	
Service delivery type: Care	
and Support	
Service delivery type:	
Treatment	1
Service delivery type:	7
PMTCT	
Sum of Service Delivery	
Type (Care, Tx and PMTCT)	8
disaggregates	



Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
7218	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State	475,357
7369	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	0
13384	Davis Memorial Hospital and Clinic	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	485,000
14260	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
17122	John Snow Inc (JSI)	Implementing Agency	U.S. Agency for International Development	GHP-State	936,289
17577	твр	твр	Redacted	Redacted	Redacted
17581	твр	ТВD	Redacted	Redacted	Redacted
17595	Ministry of Health, Guyana	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	539,400



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 7218	Mechanism Name: The Partnership for Supply Chain Management	
Funding Agency: USAID	Procurement Type: Contract	
Prime Partner Name: Partnership for Supply Chain	Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 475,357		
Applied Pipeline Amount: 585,704		
Funding Source	Funding Amount	
GHP-State	475,357	

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	145,357
Key Populations: MSM and TG	140,000
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG
Key Populations: FSW	190,000
Focus Area:	Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	7218		
Mechanism Name:	The Partnership for Supply Chain Management		
Prime Partner Name:	Partnership for Supply	Chain Management	
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and		0	0
Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	259,962	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	64,597	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	150,798	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7369	Mechanism Name: Department of Defense
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (I	Defense)
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:	
Total All Funding Sources: 0		
Applied Pipeline Amount: 235,000		
Funding Source	Funding Amount	
GHP-State	0	

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Mechanism ID:	7369		
Mechanism Name:	Department of Defense		
Prime Partner Name:	U.S. Department of Defe	ense (Defense)	
Strategic Area	Budget Code Planned Amount On Hold Amount		
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	0	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

(No data provided.)

Implementing Mechanism Details

Mechanism Name: Positively United to Support Humanity		
Procurement Type: Cooperative Agreement		
linic		
Agreement End Date: Redacted		
New Mechanism: No		
Global Fund / Multilateral Engagement: N/A		
Managing Agency:		

Total All Funding Sources: 485,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	485,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)		
Key Populations: MSM and TG	70,000	
Custom	Page 71 of 83	FACTS Info v3.8.17.0



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Key Populations: FSW	30,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers

Key Issues

(No data provided.)

Mechanism ID: 13384 Mechanism Name: Positively United to Support Humanity Prime Partner Name: Davis Memorial Hospital and Clinic			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	90,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	45,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	50,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	30,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	230,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	40,000	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14260	Mechanism Name: Peace Corps
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 38,000	
Funding Source	Funding Amount
GHP-State	0



(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	14260		
Mechanism Name:	Peace Corps		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17122	Mechanism Name: Advancing Partners and Communities Project	
Funding Agency: USAID	Procurement Type: Cooperative Agreement	
Prime Partner Name: John Snow Inc (JSI)		
Agreement Start Date: Redacted	Agreement End Date: Redacted	



TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: No	Managing Agency:	
Total All Funding Sources: 936,289		
Applied Pipeline Amount: 494,424		
Funding Source	Funding Amount	
GHP-State	936,289	

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Changing harmful gender norms and promoting
	positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	250,000
Focus Area:	Implementation of core HIV prevention interventions
	for SWs consistent with PEPFAR guidance on
	sexual prevention
Focus Area:	Training of health workers and community outreach
	workers
Focus Area:	Collection and use of strategic information on SWs
	and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	300,000



Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Key Issues

(No data provided.)

Mechanism ID: 17122			
Mechanism Name: Advancing Partners and Communities Project			
Prime Partner Name:	John Snow Inc (JSI)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	214,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	89,266	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	125,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	210,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	139,504	0



S	Strategic Area	Budget Code	Planned Amount	On Hold Amount
	Prevention	HVOP	158,519	0

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17577	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 17581	TBD: Yes	
REDACTED		

Implementing Mechanism Details

Mechanism ID: 17595	Mechanism Name: Ministry of Health, Guyana	
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement	
Prime Partner Name: Ministry of Health, Guyana		
Agreement Start Date: Redacted	Agreement End Date: Redacted	
TBD: No	New Mechanism: No	
Global Fund / Multilateral Engagement: N/A		
G2G: Yes	Managing Agency: HHS/CDC	

Total All Funding Sources: 539,400	
Applied Pipeline Amount: 250,000	
Funding Source	Funding Amount
GHP-State	539,400



(No data provided.)

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	40,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	160,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs

Key Issues

(No data provided.)

	17595 Ministry of Health, Guyana Ministry of Health, Guyana		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	НВНС	99,415	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	17,083	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	25,998	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	100,502	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,326	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	15,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	МТСТ	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	157,160	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	23,916	0

(No data provided.) Custom 2015-11-24 15:39 EST





Agency Information - Costs of Doing Business U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services		34,277		34,277	0
ICASS		46,756		46,756	0
Indirect Costs		17,133		17,133	0
Staff Program Travel		76,740		76,740	0
USG Staff Salaries and Benefits		628,726		628,726	0
Total	0	803,632	0	803,632	0

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		0		0	13,140
Staff Program Travel		0		0	6,000
USG Staff Salaries and Benefits		0		0	45,860
Total	0	0	0	0	65,000

U.S. Department of Health and Human Services/Centers for Disease Control and



Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing	120,000			120,000	0
Computers/IT Services	30,000			30,000	0
ICASS	290,000			290,000	0
Management Meetings/Professio nal Development	50,000	12,000		62,000	0
Non-ICASS Administrative Costs		24,050		24,050	0
Staff Program Travel		5,000		5,000	0
USG Staff Salaries and Benefits	85,000	297,858		382,858	0
Total	575,000	338,908	0	913,908	0

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
ICASS		22,000		22,000	0
Management Meetings/Professio nal Development		20,589		20,589	0
Staff Program Travel		10,000		10,000	0
USG Staff Salaries		42,411		42,411	0



and Benefits					
Total	0	95,000	0	95,000	0

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		749		749	1,448
Peace Corps Volunteer Costs		67,767		67,767	0
USG Staff Salaries and Benefits				0	10,623
Total	0	68,516	0	68,516	12,071